This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Jan;9(1):1.

doi: 10.1038/nrrheum.2012.222. Epub 2012 Dec 11.

First face-off in RA biologic therapy declared a draw

PMID: 23229451
DOI: 10.1038/nrrheum.2012.222

Comment

First face-off in RA biologic therapy declared a draw

Emma Leah. Nat Rev Rheumatol. 2013 Jan.

. 2013 Jan;9(1):1.

doi: 10.1038/nrrheum.2012.222. Epub 2012 Dec 11.

Author

PMID: 23229451
DOI: 10.1038/nrrheum.2012.222

No abstract available

PubMed Disclaimer

Comment on

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R. Weinblatt ME, et al. Arthritis Rheum. 2013 Jan;65(1):28-38. doi: 10.1002/art.37711. Arthritis Rheum. 2013. PMID: 23169319 Free PMC article. Clinical Trial.

References

1. Nat Rev Rheumatol. 2011 Apr;7(4):205-15 - PubMed
1. Nat Rev Rheumatol. 2011 Oct 11;7(11):639-52 - PubMed
1. Arthritis Rheum. 2013 Jan;65(1):28-38 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.